This is what the shareholding structure of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) looks like

If you want to know who actually controls Theseus Pharmaceuticals, Inc. (NASDAQ: THRX), then you will need to look at the makeup of its share register. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I like to see at least a little insider ownership. As Charlie Munger said, “Show me the incentive and I’ll show you the result.

Theseus Pharmaceuticals is a smaller company with a market cap of US $ 369 million, so it may still go under the radar of many institutional investors. In the graphic below, we can see that the institutions are visible on the share register. We can zoom in on the different property groups to find out more about Theseus Pharmaceuticals.

Breakdown of the NasdaqGS property: THRX January 7, 2022

What does institutional ownership tell us about Theseus Pharmaceuticals?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it’s included in a major index. . We would expect most businesses to have some institutions listed, especially if they are growing.

As you can see, institutional investors have a significant stake in Theseus Pharmaceuticals. This implies that analysts working for these institutions have reviewed the action and appreciate it. But like everyone else, they could be wrong. If several institutions change their mind about a stock at the same time, you could see the stock price drop quickly. So it’s worth checking out Theseus Pharmaceuticals profit history below. Of course, the future is what really matters.

profit and revenue growthNasdaqGS: THRX Earnings and Revenue Growth January 7, 2022

Theseus Pharmaceuticals is not owned by hedge funds. OrbiMed Advisors LLC is currently the largest shareholder, with 45% of the shares outstanding. With 10% and 9.7% of shares outstanding, respectively, FMR LLC and Foresite Capital Management, LLC are the second and third largest shareholders. Additionally, CEO Timothy Clackson owns 0.9% of the company’s shares.

To make our study more interesting, we found that the top 2 shareholders have a controlling stake in the company, which means that they are powerful enough to influence the decisions of the company.

While studying the institutional ownership of a company can add value to your research, it is also recommended that you research analyst recommendations to better understand the expected performance of a stock. There are a reasonable number of analysts covering the stock, so it can be helpful to know their overall vision for the future.

Insider Property of Theseus Pharmaceuticals

The definition of business insiders can be subjective and vary from jurisdiction to jurisdiction. Our data reflects individual insiders, capturing at least board members. The management of the company manages the company, but the CEO will report to the board of directors, even if he is a member of the board.

Insider ownership is positive when it indicates that executives think like the real owners of the company. However, strong insider ownership can also confer immense power on a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares of Theseus Pharmaceuticals, Inc. Its market capitalization is only US $ 369 million, and insiders have shares worth US $ 19 million, in their own name. . It shows at least some alignment. You can click here to see if these insiders bought or sold.

General public property

With a 22% stake, the general public, made up mainly of individual investors, has some influence over Theseus Pharmaceuticals. While this property size may not be enough to influence a policy decision in their favor, they can still have a collective impact on company policies.

Private shareholders

Private equity firms hold 54% of the capital of Theseus Pharmaceuticals. This suggests that they can influence key policy decisions. Some might like this, as sometimes private capital is activists holding management to account. But other times, the private equity sells, after you have taken the company to the stock market.

Public enterprise ownership

It seems to us that state-owned companies own 4.3% of Theseus Pharmaceuticals. We cannot be sure, but it is quite possible that it is a strategic issue. Companies can be similar or work together.

Next steps:

It’s always worth thinking about the different groups that own shares in a company. But to better understand Theseus Pharmaceuticals, there are many other factors that we need to consider. For example, we discovered 4 warning signs for Theseus Pharmaceuticals (2 shouldn’t be ignored!) Which you should be aware of before investing here.

If you are like me, you might want to ask yourself if this business will grow or shrink. Fortunately, you can check this free report showing analysts’ forecasts for its future.

NB: The figures in this article are calculated from data for the last twelve months, which refer to the 12-month period ending on the last date of the month of date of the financial statement. This may not be consistent with the figures in the annual report for the entire year.

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at)

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in any of the stocks mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Comments are closed.